Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...

Shares of Incyte Corp. slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the stock ...

Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price ...

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the povorcitinib/povo ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...